Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
J Appl Toxicol ; 43(4): 534-556, 2023 04.
Article in English | MEDLINE | ID: mdl-36227735

ABSTRACT

Herpes simplex virus type 2 (HSV-2) is the most common cause of genital disease worldwide. The development of an effective HSV-2 vaccine would significantly impact global health based on the psychological distress caused by genital herpes for some individuals, the risk transmitting the infection from mother to infant, and the elevated risk of acquiring HIV-1. Five nonclinical safety studies were conducted with the replication defective HSV529 vaccine, alone or adjuvanted with GLA-SE, and the G103 subunit vaccine containing GLA-SE. A biodistribution study was conducted in guinea pigs to evaluate distribution, persistence, and shedding of HSV529. A preliminary immunogenicity study was conducted in rabbits to demonstrate HSV529-specific humoral response and its enhancement by GLA-SE. Three repeated-dose toxicity studies, one in guinea pigs and two in rabbits, were conducted to assess systemic toxicity and local tolerance of HSV529, alone or adjuvanted with GLA-SE, or G103 containing GLA-SE. Data from these studies show that both vaccines are safe and well tolerated and support the ongoing HSV-2 clinical trial in which the two vaccine candidates will be given either sequentially or concomitantly to explore their potential synergistic and incremental effects.


Subject(s)
Antibodies, Viral , Herpesvirus 2, Human , Humans , Animals , Guinea Pigs , Rabbits , Tissue Distribution , Viral Envelope Proteins , Adjuvants, Immunologic , Vaccines, Subunit
2.
Vaccine ; 37(22): 2960-2966, 2019 05 16.
Article in English | MEDLINE | ID: mdl-31010716

ABSTRACT

Potency assays for vaccine products are an important regulatory requirement, and are used to assess product quality and consistency prior to lot release for clinical testing. Ideally they measure an established correlate of efficacy or protection. In cases where there is no known correlate of protection, however, a functional assay that measures a biological response to a vaccine can be applied as a potency assay. Here we describe an in vitro assay which quantitatively measures human T cell activation as a biological response to the TB vaccine candidate H4-IC31. The Cytokine Secretion Assay (CSA) is based on the ability of peripheral blood mononuclear cells (PBMCs) from a Bacillus Calmette-Guérin (BCG)-vaccinated human donor to process and respond to H4-IC31. The ability of H4-IC31 to stimulate a cellular immune response is measured through the quantification of secreted IFNγ and is reported as relative stimulatory activity (RSA) compared to an in-house reference standard. The CSA is specific to the H4-IC31 vaccine, determines the RSA of H4-IC31 in the range of 50% to 150% of the reference standard, and is stability indicating as it detects differences in RSA between intact and heat treated H4-IC31. Although the CSA does not provide a link to clinical efficacy, it fulfills the critical requirements for a biological potency test to assess TB vaccine candidates and can be used along with biochemical and immunochemical assays to define a product profile during clinical development, while eliminating the use of animals for product testing.


Subject(s)
Immunity, Cellular/immunology , Tuberculosis Vaccines/immunology , BCG Vaccine/immunology , Cells, Cultured , Humans , Immunization , Interferon-gamma/metabolism , Mycobacterium tuberculosis/immunology
3.
J Clin Virol ; 96: 99-104, 2017 11.
Article in English | MEDLINE | ID: mdl-29035763

ABSTRACT

BACKGROUND: In clinical trials of cytomegalovirus (CMV) glycoprotein B (gB) vaccines, CMV infection is detected by first depleting serum of anti-gB antibodies and then measuring anti-CMV antibodies with a commercially available enzyme-linked immunosorbent assay (ELISA) kit, with confirmation of positive findings by immunoblot. OBJECTIVES: Identification of CMV immunoantigens for the development of an ELISA that detects specifically CMV infection in clinical samples from individuals immunized with gB vaccines. STUDY DESIGN: Sensitivity and specificity of ELISAs using antigenic regions of CMV proteins UL83/pp65, UL99/pp28, UL44/pp52, UL80a/pp38, UL57, and UL32/pp150 were measured. RESULTS: An IgG ELISA using a UL32/pp150 [862-1048] capture peptide was the most specific (93.7%) and sensitive (96.4%) for detecting CMV-specific antibodies in sera. The ELISA successfully detected CMV-specific antibodies in 22 of 22 sera of subjects who had been vaccinated with a gB vaccine but who had later been infected with CMV. The ELISA was linear over a wide range of CMV concentrations (57-16,814 ELISA units/mL) and was reproducible as indicated by a 5% intra-day and 7% inter-day coefficients of variation. The signal was specifically competed by UL32/pp150 [862-1048] peptide but not by CMV-gB or herpes simplex virus 2 glycoprotein D. Lipid and hemoglobin matrix did not interfere with the assay. CONCLUSION: The UL32/pp150 [862-1048] IgG ELISA can be used for the sensitive and specific detection of CMV infection in gB-vaccinated individuals.


Subject(s)
Antibodies, Viral/blood , Clinical Trials as Topic , Cytomegalovirus Infections/diagnosis , Cytomegalovirus Infections/prevention & control , Cytomegalovirus Vaccines/administration & dosage , Diagnostic Tests, Routine/methods , Enzyme-Linked Immunosorbent Assay/methods , Antigens, Viral/immunology , Humans , Immunoglobulin G/blood , Sensitivity and Specificity , Vaccines, Synthetic/administration & dosage
4.
Vaccine ; 34(7): 914-22, 2016 Feb 10.
Article in English | MEDLINE | ID: mdl-26768129

ABSTRACT

Intradermal (ID) vaccination constitutes a promising approach to induce anti-infectious immunity. This route of immunization has mostly been studied with influenza split-virion vaccines. However, the efficacy of ID vaccination for sub-unit vaccines in relation to underlying skin innate immunity remains to be explored for wider application in humans. Relevant animal models that more closely mimic human skin immunity than the widely used mouse models are therefore necessary. Here, we show in domestic swine, which shares striking anatomic and functional properties with human skin, that a single ID delivery of pseudorabies virus (PRV) glycoproteins without added adjuvant is sufficient to trigger adaptive cellular and humoral immune responses, and to confer protection from a lethal respiratory infection with PRV. Analysis of early events at the skin injection site revealed up-regulation of pro-inflammatory cytokine and chemokine genes, recruitment of neutrophils and monocytes and accumulation of inflammatory DC. We further show that the sustained induction of pro-inflammatory cytokine genes results from the combined effects of skin puncture, liquid injection in the dermis and viral antigens. These data highlight that immune protection against respiratory infection can be induced by ID vaccination with a subunit vaccine and reveal that adjuvant requirements are circumvented by the mechanical and antigenic stress caused by ID injection, which triggers innate immunity and mobilization of inflammatory DC at the immunization site. ID vaccination with sub-unit vaccines may thus represent a safe and efficient solution for protection against respiratory infections in swine and possibly also in humans, given the similarity of skin structure and function in both species.


Subject(s)
Immunity, Innate , Pseudorabies/prevention & control , Skin/immunology , Viral Envelope Proteins/immunology , Viral Vaccines/administration & dosage , Adjuvants, Immunologic , Animals , Antibodies, Neutralizing/blood , Antibodies, Viral/blood , Cytokines , Dendritic Cells/immunology , Female , Immunity, Cellular , Immunity, Humoral , Injections, Intradermal , Swine , Vaccination/methods , Vaccines, Subunit/administration & dosage , Vaccines, Subunit/immunology , Viral Vaccines/immunology
5.
Int J Pharm ; 486(1-2): 99-111, 2015.
Article in English | MEDLINE | ID: mdl-25794609

ABSTRACT

We describe the development, analytical characterization, stability and preclinical efficacy of AF04, a combination adjuvant comprising the synthetic toll-like receptor 4 (TLR4) agonist, E6020, formulated in AF03, a thermoreversible squalene emulsion. By using AF04 with the recombinant major outer membrane protein of Chlamydia trachomatis (Ct-MOMP) and with the recombinant surface glycoprotein gB from human cytomegalovirus (CMV-gB) as model antigens, we show that AF03 and E6020 can synergize to augment specific antibody and Th-1 cellular immune responses in mice. In terms of formulation, we observe that the method used to incorporate E6020 into AF03 affects its partition between the oil and water phases of the emulsion which in turn has a significant impact on the tolerability (IV pyrogenicity test in rabbits) of this novel adjuvant combination.


Subject(s)
Adjuvants, Immunologic , Bacterial Outer Membrane Proteins/immunology , Squalene , Toll-Like Receptor 4/agonists , Vaccines , Viral Proteins/immunology , Adjuvants, Immunologic/chemistry , Adjuvants, Immunologic/pharmacology , Animals , Antibodies, Bacterial/blood , Antibodies, Viral/blood , Antigens, Bacterial/immunology , Antigens, Viral/immunology , Cell Line , Chlamydia trachomatis , Cytokines/immunology , Cytomegalovirus , Dendritic Cells/drug effects , Dendritic Cells/immunology , Drug Design , Emulsions , Female , Glycoproteins/immunology , Humans , Immunoglobulin G/blood , Leukocytes, Mononuclear , Mice, Inbred C57BL , Rabbits , Squalene/chemistry , Squalene/pharmacology , Vaccines/chemistry , Vaccines/pharmacology
6.
Vaccine ; 28(18): 3076-9, 2010 Apr 19.
Article in English | MEDLINE | ID: mdl-20193791

ABSTRACT

Pandemic influenza vaccines have been manufactured using the A/California/07/2009 (H1N1) strain as recommended by the World Health Organization. We evaluated in mice the immunogenicity of pandemic (H1N1) 2009 vaccine and the impact of prior vaccination against seasonal trivalent influenza vaccines (TIV) on antibody responses against pandemic (H1N1) 2009. In naïve mice, a single dose of unadjuvanted H1N1 vaccine (3 microg of HA) was shown to elicit hemagglutination inhibition (HI) antibody titers >40, a titer associated with protection in humans against seasonal influenza. A second vaccine dose of pandemic (H1N1) 2009 vaccine strongly increased these titers, which were consistently higher in mice previously primed with TIV than in naïve mice. At a low immunization dose (0.3 microg of HA), the AF03-adjuvanted vaccine elicited higher HI antibody titers than the corresponding unadjuvanted vaccines in both naïve and TIV-primed animals, suggesting a potential for antigen dose-sparing. These results are in accordance with the use in humans of a split-virion inactivated pandemic (H1N1) 2009 vaccine formulated with or without AF03 adjuvant to protect children and young adults against influenza A (H1N1) 2009 infection.


Subject(s)
Adjuvants, Immunologic/administration & dosage , Antibodies, Viral/blood , Influenza A Virus, H1N1 Subtype/immunology , Influenza Vaccines/immunology , Vaccination/methods , Animals , Female , Hemagglutination Inhibition Tests , Immunization, Secondary/methods , Mice , Mice, Inbred BALB C
7.
J Immunol ; 168(8): 3874-80, 2002 Apr 15.
Article in English | MEDLINE | ID: mdl-11937541

ABSTRACT

Lymphocyte activation gene-3 (LAG-3) is an MHC class II ligand expressed on activated T and NK cells. A LAG-3Ig fusion protein has been used in mice as an adjuvant protein to induce antitumor responses and specific CD8 and CD4 Th1 responses to nominal Ags. In this work we report on the effect of LAG-3Ig on the maturation and activation of human monocyte-derived dendritic cells (DC). LAG-3Ig binds MHC class II molecules expressed in plasma membrane lipid rafts on immature human DC and induces rapid morphological changes, including the formation of dendritic projections. LAG-3Ig markedly up-regulates the expression of costimulatory molecules and the production of IL-12 and TNF-alpha. Consistent with this effect on DC maturation, LAG-3Ig disables DC in their capacity to capture soluble Ags. These events are associated with the acquisition of professional APC function, because LAG-3Ig increases the capacity of DC to stimulate the proliferation and IFN-gamma response by allogeneic T cells. These effects were not observed when using ligation of MHC class II by specific mAb. Class II-mediated signals induced by a natural ligand, LAG-3, lead to complete maturation of DC, which acquire the capacity to trigger naive T cells and drive polarized Th1 responses.


Subject(s)
Antigens, CD , Dendritic Cells/immunology , Dendritic Cells/metabolism , Membrane Proteins/physiology , Animals , Antigen-Presenting Cells/cytology , Antigen-Presenting Cells/immunology , Antigen-Presenting Cells/metabolism , CHO Cells , Cell Adhesion/immunology , Cell Differentiation/immunology , Cell Size/immunology , Cells, Cultured , Cricetinae , Dendritic Cells/cytology , Down-Regulation/immunology , Humans , Immunophenotyping , Interleukin-12/metabolism , Lymphocyte Activation/immunology , Membrane Proteins/metabolism , Protein Binding/immunology , Recombinant Fusion Proteins/metabolism , Serum Albumin, Bovine/immunology , Serum Albumin, Bovine/metabolism , T-Lymphocytes/immunology , Tumor Necrosis Factor-alpha/metabolism , Lymphocyte Activation Gene 3 Protein
SELECTION OF CITATIONS
SEARCH DETAIL
...